A shadow over the promising inhaled interferon beta COVID-19 therapy has been cleared with the discovery that although it appears to increase levels of.
11 Jan 2021 Share:
While ACE2 proteins are known to be the vehicle used by COVID-19 to enter the nose and lungs, the previously worrying increase in ACE2 found to occur as a result of interferon treatment has been shown to include only a new, short version of the protein that cannot bind the SARS-CoV-2 virus. This both bodes well for interferon treatments and might even provide some protection against the virus.
A shadow over the promising inhaled interferon beta COVID-19 therapy has been cleared with the discovery that although it appears to increase levels of ACE2 protein - coronavirus key entry point into nose and lung cells - it predominantly increases levels of a short version of that protein, which the virus cannot bind to.
A shadow over the promising inhaled interferon beta COVID-19 therapy has been cleared with the discovery that although it appears to increase levels of ACE2 protein - coronavirus key entry point into nose and lung cells - it predominantly increases levels of a short version of that protein, which the virus cannot bind to.